Latest stories on IMNN
Imunon enters CRADA with National Cancer Institute for IMNN-001 development
The Fly63 · neutralproduct/pr
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Business Insider63 · neutralproduct/pr
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
GlobeNewswire67 · bullishproduct/pr
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Business Insider56 · neutralproduct/pr
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
GlobeNewswire56 · neutralproduct/pr
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
StockTitan63 · neutralproduct/pr
Imunon Earnings Call Highlights Survival Gains, Cash Needs
TipRanks56 · neutralearnings
Imunon (IMNN) Q2 2026 Earnings Call Transcript
The Motley Fool50 · neutralearnings
Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation
Seeking Alpha58 · neutralproduct/pr
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Imunon, Inc. (IMNN) files 8-K
SEC 8-K50 · neutralgeneral
Imunon reports Q2 EPS (54c), consensus (50c)
The Fly52 · neutralearnings
Imunon GAAP EPS of -$0.54 beats by $0.50
Seeking Alpha56 · neutralearnings
Imunon, Inc. (IMNN) files 8-K
SEC 8-K50 · neutralgeneral
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
StockTitan54 · neutralgeneral
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
Business Insider50 · neutralgeneral
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
StockTitan67 · bullishproduct/pr
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
StockTitan63 · neutralproduct/pr
IMUNON announces executive transition: Josh Blacher appointed interim CFO as Jeffrey Church retires
Seeking Alpha50 · neutralgeneral
Imunon, Inc. (IMNN) files 8-K
SEC 8-K50 · neutralgeneral
Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor Forum - Slideshow
Seeking Alpha50 · neutralgeneral
IMUNON to Present at the Life Sciences Investor Forum on June 25th | IMNN Stock News
StockTitan56 · neutralgeneral
Imunon, Inc. (IMNN) files 8-K
SEC 8-K50 · neutralgeneral